Drug General Information
Drug ID	D0P0KN
Former ID	DNCL002191
Drug Name	TG02
Drug Type	Small molecular drug
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 1	[531820]
Structure		Download 2D MOL 3D MOL
Formula	C23H24N4O
Canonical SMILES	CN1CC=CCCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1
InChIKey	VXBAJLGYBMTJCY-NSCUHMNNSA-N
PubChem Compound ID	16739650
PubChem Substance ID	26698510, 46148847, 136923474, 136967258, 137926659, 152258630, 160647465, 172919550, 185990486, 223405965, 227098343, 228421311, 252451715, 252480863
Target and Pathway
Target(s)	Cell division protein kinase 2	Target Info	Modulator	[531820]
KEGG Pathway	FoxO signaling pathway
	Cell cycle
	Oocyte meiosis
	p53 signaling pathway
	PI3K-Akt signaling pathway
	Progesterone-mediated oocyte maturation
	Hepatitis B
	Measles
	Herpes simplex infection
	Epstein-Barr virus infection
	Pathways in cancer
	Viral carcinogenesis
	Prostate cancer
	Small cell lung cancer
NetPath Pathway	TCR Signaling Pathway
PANTHER Pathway	p53 pathway
	p53 pathway feedback loops 2
Pathway Interaction Database	Regulation of nuclear SMAD2/3 signaling
	Signaling events mediated by PRL
	p73 transcription factor network
	E2F transcription factor network
	ATR signaling pathway
	mTOR signaling pathway
	IL2-mediated signaling events
	FoxO family signaling
	FOXM1 transcription factor network
	BARD1 signaling events
	p53 pathway
	Regulation of retinoblastoma protein
Reactome	G0 and Early G1
	Activation of ATR in response to replication stress
	Regulation of APC/C activators between G1/S and early anaphase
	SCF(Skp2)-mediated degradation of p27/p21
	Senescence-Associated Secretory Phenotype (SASP)
	DNA Damage/Telomere Stress Induced Senescence
	Processing of DNA double-strand break ends
	G2 Phase
	Orc1 removal from chromatin
	Cyclin E associated events during G1/S transition
	Cyclin A/B1 associated events during G2/M transition
	p53-Dependent G1 DNA Damage Response
	Cyclin A:Cdk2-associated events at S phase entry
	Meiotic recombination
	Factors involved in megakaryocyte development and platelet production
WikiPathways	DNA Damage Response
	ID signaling pathway
	DNA Replication
	G1 to S cell cycle control
	M/G1 Transition
	S Phase
	Meiotic Recombination
	Aryl Hydrocarbon Receptor
	ATM Signaling Pathway
	Retinoblastoma (RB) in Cancer
	Spinal Cord Injury
	Integrated Pancreatic Cancer Pathway
	Oncostatin M Signaling Pathway
	Prostate Cancer
	Signaling Pathways in Glioblastoma
	TSH signaling pathway
	Integrated Breast Cancer Pathway
	Integrated Cancer pathway
	Synthesis of DNA
	Regulation of DNA replication
	Mitotic G2-G2/M phases
	Mitotic G1-G1/S phases
	Factors involved in megakaryocyte development and platelet production
	Cell Cycle
	APC/C-mediated degradation of cell cycle proteins
	Cell Cycle Checkpoints
	miRNA Regulation of DNA Damage Response
References
Ref 531820	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
Ref 531820	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.